Open Access<p>Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States</p>
Author(s) -
Lisa M. Hess,
Michael Grabner,
Liya Wang,
Astra M. Liepa,
Xiaohong Ivy Li,
Zhanglin Lin Cui,
Lee Bowman,
William R. Schelman
Publication year - 2020
Publication title -
pragmatic and observational research
Language(s) - English
Resource type - Journals
ISSN - 1179-7266
DOI - 10.2147/por.s241427
Subject(s) - ramucirumab , trastuzumab , medicine , real world data , cancer , psychological intervention , oncology , drug , intensive care medicine , pharmacology , breast cancer , psychiatry , data science , computer science
As real-world data resources expand and improve, there will increasingly be opportunities to study the effectiveness of interventions. There is a need to ensure that study designs explore potential sources of bias and either acknowledge or mitigate them, in order to improve the accuracy of findings. The objective of this study was to understand newly approved drug utilization patterns in real-world clinical settings over time.